{"id":"neladalkib-nvl-655","safety":{"commonSideEffects":[{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Elevated transaminases"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"Neladalkib targets anaplastic lymphoma kinase (ALK), a receptor tyrosine kinase that is aberrantly activated in certain cancers through chromosomal translocations or mutations. By inhibiting ALK phosphorylation and downstream signaling, the drug suppresses proliferation of ALK-dependent tumor cells. It is being developed for ALK-positive malignancies, particularly non-small cell lung cancer and other solid tumors.","oneSentence":"Neladalkib is a selective ALK (anaplastic lymphoma kinase) inhibitor that blocks ALK-driven signaling in cancer cells.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:22:50.154Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"ALK-positive non-small cell lung cancer"},{"name":"ALK-positive solid tumors"}]},"trialDetails":[{"nctId":"NCT06765109","phase":"PHASE3","title":"Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC","status":"RECRUITING","sponsor":"Nuvalent Inc.","startDate":"2025-07-17","conditions":"Non-small Cell Lung Cancer, Anaplastic Lymphoma Kinase-positive","enrollment":450},{"nctId":"NCT06834074","phase":"","title":"Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors","status":"AVAILABLE","sponsor":"Nuvalent Inc.","startDate":"","conditions":"Non Small Cell Lung Cancer, ALK-positive Non-small Cell Lung Cancer (NSCLC)","enrollment":""},{"nctId":"NCT05384626","phase":"PHASE1, PHASE2","title":"A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1)","status":"RECRUITING","sponsor":"Nuvalent Inc.","startDate":"2022-06-09","conditions":"Locally Advanced Solid Tumor, Metastatic Solid Tumor","enrollment":840}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Neladalkib (NVL-655)","genericName":"Neladalkib (NVL-655)","companyName":"Nuvalent Inc.","companyId":"nuvalent-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Neladalkib is a selective ALK (anaplastic lymphoma kinase) inhibitor that blocks ALK-driven signaling in cancer cells. Used for ALK-positive non-small cell lung cancer, ALK-positive solid tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}